Iambic Therapeutics, Inc. Common Stock (IAM)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
18.91 USD
+2.91
(18.188%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 19.00 +0.09 (0.476%) ⇧ (Oct. 15, 2026, 7:51 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 2:05 a.m. EDT
The security presents a complete void of investable characteristics. There is absolutely no price history available to assess momentum, technical setups, or even the basic viability of the business over time. Furthermore, the company pays no dividend, offering zero income to investors. Without any historical data to gauge performance or any news flow to suggest a turnaround, the instrument offers no edge for either short-term trading or long-term holding. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.236 |
| Revenue per Share | 0.827 |
| Market Cap | 896,349,056 |
| Website | https://www.iambic.ai |
| Attribute | Value |
|---|---|
| Address1 | 5,627 Oberlin Drive |
| Address2 | Suite 120 |
| Bid | 18.01 |
| Bid Size | 20 |
| Book Value | -9.852 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.91 |
| Current Ratio | 4.593 |
| Custom Price Alert Confidence | HIGH |
| Day High | 19.7 |
| Day Low | 16.15 |
| Debt To Equity | 3.236 |
| Display Name | Iambic Therapeutics |
| Ebitda | -98,806,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.455 |
| Enterprise To Revenue | 34.944 |
| Enterprise Value | 637,765,952 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 19.7 |
| Fifty Two Week High Change | -0.7900009 |
| Fifty Two Week High Change Percent | -0.04010157 |
| Fifty Two Week Low | 16.15 |
| Fifty Two Week Low Change | 2.7600002 |
| Fifty Two Week Low Change Percent | 0.17089786 |
| Fifty Two Week Range | 16.15 - 19.7 |
| Financial Currency | USD |
| Float Shares | 4,174,188 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 171 |
| Fullday Change | 3.0 |
| Fullday Change Percent | 18.75 |
| Fullday Price | 18.91 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -83,492,000 |
| Has Pre Post Market Data | 1 |
| Implied Shares Outstanding | 47,400,796 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-10-15 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California. |
| Long Name | Iambic Therapeutics, Inc. Common Stock |
| Market | us_market |
| Market Cap | 896,349,056 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_697621497 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -94,246,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Open | 16.15 |
| Operating Cashflow | -65,726,000 |
| Operating Margins | -4.19595 |
| Phone | (619) 330-5499 |
| Post Market Change | 0.09000015 |
| Post Market Change Percent | 0.47593948 |
| Post Market Price | 19.0 |
| Post Market Time | 1,792,108,281 |
| Previous Close | 16.0 |
| Price Hint | 2 |
| Price To Book | -1.9194071 |
| Price To Sales Trailing12 Months | 49.112328 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.513 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 2.9099998 |
| Regular Market Change Percent | 18.1875 |
| Regular Market Day High | 19.7 |
| Regular Market Day Low | 16.15 |
| Regular Market Day Range | 16.15 - 19.7 |
| Regular Market Open | 16.15 |
| Regular Market Previous Close | 16.0 |
| Regular Market Price | 18.91 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 2,006,424 |
| Revenue Growth | 2.247 |
| Revenue Per Share | 0.827 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 47,400,796 |
| Short Name | Iambic Therapeutics, Inc. Common Stock |
| Source Interval | 15 |
| State | CA |
| Symbol | IAM |
| Total Cash | 207,878,000 |
| Total Cash Per Share | 8.806 |
| Total Debt | 5,226,000 |
| Total Revenue | 18,251,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 2,006,424 |
| Website | https://www.iambic.ai |
| Zip | 92,121 |